Clinical Trial Update: Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safe and effective dose of romiplostim in patients with myelodysplastic syndrome receiving hypomethylating agents; results completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Thrombocytopenia

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Amgen | Conditions: MDS, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2011-04-05